Our Dear GeorgeGeorge Adams is a master at what he was hired for; he was bought onboard to raise capital, and that he has always been able to accomplish, sometimes in a big way.
His ability to monetize the technology is another story. We are literally five years past the first effort to sell our technology to what we were told was an eagerly waiting medical community. There have been alot of wrong turns along the way and over optimistic predictions from our CEO. The problem with Ventripoint is that the share price always returns to where it began because there is never consecutive milestone news releases to hold the stock value and propel it higher. Management has a sizable chunk of cash right now, so I wouldn't hold my breath that huge news is imminent.